Albin JEANNE

Albin JEANNE has a diverse work experience in the field of biotechnology and research. Albin is currently working as the Chief Executive Officer of Apmonia Therapeutics, a biotechnology company that specializes in immunotherapies for cancers and other diseases. Albin played a key role in establishing Apmonia Therapeutics as a spinoff of their research work at the University of Reims Champagne-Ardenne.

Prior to their current role, Albin worked as a Project Manager at SATT Nord, where they focused on maturing a patent for an innovative anti-cancer peptide. SATT Nord is a technology transfer acceleration company that acts as an interface between companies and public research institutes in the northern regions of France.

Earlier in their career, Albin was involved in teaching and supervision activities at the University of Reims Champagne-Ardenne. Albin conducted tutorials, practical work, and lectures in various subjects related to biochemistry, molecular biology, bioinformatics, genetics, and cancer models. Albin also supervised M.Sc. students during this time.

Albin's work experience also includes being a doctoral researcher at the Centre national de la recherche scientifique. Albin conducted research in the MEDyC research unit, where they focused on studying the interaction between thrombospondin-1 and its receptor CD47 in the context of cancer cell microenvironment.

Overall, Albin JEANNE has a strong background in biotechnology, research, and academia, with expertise in immunotherapies, technology transfer, and cancer biology.

Albin JEANNE's education history is as follows:

From 2019 to 2020, Albin attended HEC Paris and completed a Challenge+ degree in Innovation & Entrepreneurship.

From 2018 to 2019, Albin participated in the Starter Class program at Innovact Incubation by SEMIA, focusing on Entrepreneurship/Entrepreneurial Studies.

Also in 2018 to 2019, Albin studied at the Institut de Formation des Industries de Santé (IFIS) in the field of Translational life sciences R&D, although the degree obtained from this institution is not specified.

From 2010 to 2013, Albin pursued a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology at the Université de Reims Champagne-Ardenne.

In addition, in 2011, Albin obtained a university degree on animal experiments (level 1) from the Université de Reims Champagne-Ardenne.

From 2009 to 2010, Albin completed a postgraduate degree following a Master (research Master 2) in Cells and Extracellular Microenvironment Interactions at the Université de Reims Champagne-Ardenne.

In 2008 to 2009, Albin earned a Master's degree (Master 1) in Biology - Chemistry - Health from the Université de Reims Champagne-Ardenne.

Lastly, from 2005 to 2008, Albin completed a First degree (Licence) in Science & Technology - Biochemistry at the Université de Reims Champagne-Ardenne.